Radiation doses from digital breast tomosynthesis is comparable to and could be lower than conventional two-view full-field digital mammography.
Radiation doses from digital breast tomosynthesis is comparable to and could be lower than conventional two-view full-field digital mammography, show findings of a study published in the April issue of Radiology.
Researchers from Emory University School of Medicine in Atlanta, Ga., compared dose levels of digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM) by using compressible water-oil mixture breast phantoms of varying sizes to determine how much radiation dose would be used for varying sizes and glandular compositions of breasts.
When comparing doses with the “average” breast (compressed thickness of 5 cm, 50 percent glandular fraction), a DBT acquisition resulted in 1.30 mGy, only an 8 percent higher mean glandular dose than the FFDM acquisition of 1.20 mGy. For a thicker breast sample (6.0 cm and 14.3 percent glandular fraction), a DBT acquisition was 2.12 mGy, which was 83 percent higher than an FFDM acquisition of 1.16 mGy.
RELATED: Practices Adjust Workflow IT for Tomosynthesis Adoption
Although the thicker breast had a higher dose, the researchers pointed out that this was still lower than the 3 mGy limit for a single-view conventional study, which is set by the Mammography Quality Standards Act.
Potentially, screening DBT could reduce the recall rate, reducing the number of repeat scans, which reduces women’s overall radiation dose rate.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.